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Abstract
Background: The rare incidence of neuroendocrine neoplasms (NENs) has contributed to a paucity of large
epidemiologic studies of patients with this condition. We investigated the occurrence and clinicopathologic
features of NENs in Greece.
Methods: Between October 2010 and November 2012 we collected data on 246 newly diagnosed patients from a
broad-based multi-institutional registry that comprises eight academic and hospital sites in Greece. The WHO 2010
pathologic classification and the 7th AJCC Staging system was applied in all cases.
Results: Of all patients 94 % had a sporadic and 6 % a multiple endocrine neoplasia tumor; 63.4 % were
gastroenteropancreatic-(GEP)-NENs, 17.9 % Head & Neck NENs, 9.8 % NENs of Unknown Primary, 6.5 % Lung
NENs and 2.4 % Pheochromocytomas. Gastric and pancreatic NENs were the most common primary sites.
Poorly differentiated neuroendocrine carcinomas (NEC) were 9.3 %, all sporadic. Fifteen percent of patients
were asymptomatic at presentation, 24 % had a first symptom of the disease related to endocrine syndrome
and 61 % had symptoms related to locally advanced or metastatic disease. Metastatic disease was established
in 25 % of tumors most frequently in the GEP NEN group. Findings are presented according to Ki-67 distribution. MRI
had a higher diagnostic positive yield than Octreoscan. Somatostatin analogs, lanreotide and octreotide acetate, were
prescribed at 38.5 & 61.5 % of NEN patients respectively and were found to be equally effective at providing
symptomatic relief.
Conclusions: This is to our knowledge the first study of a Greek tumor registry and one of the few European Registries
providing information regarding clinicopathologic characteristics and therapies in patients with neuroendocrine tumors
of various origin sites, beyond GEP NENs.
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Background
Neuroendocrine neoplasms (NENs) are a heterogeneous
group of tumors arising from cells of the diffuse body
neuroendocrine system most commonly in the gastro-
intestinal tract.
Since 1907, when originally described as benign tu-
mors by Oberndorfer [1], the nomenclature and classifi-
cation of NENs has changed several times, making the
collection of epidemiological information and the com-
parison among studies published in the literature very
difficult. Gastroenteropancreatic NENs (GEP NENs)
were recently redefined according to the updated patho-
logical and immunohistochemical criteria established by
WHO [2]. Irrespective of the specific site of origin, GEP
NENs are classified as ‘well differentiated’, ‘moderately dif-
ferentiated’ or ‘poorly differentiated neuroendocrine car-
cinomas GEP-NEC’. Additionally the classification is
based on the Ki-67 labeling index (LI) that categorizes
GEP NENs into the three groups: ≤ 2, 3–20 and >20 % [2].
Despite a small number of national multicentric regis-
try studies and an even smaller number of epidemio-
logical studies the real incidence of NENs is unclear.
This can be a reason that explains the discrepancy be-
tween the estimated incidence that differs between gen-
ders, races and among countries and continents [3, 4].
There are several explanations for this phenomenon
most importantly that previous histopathologic classifi-
cations have been substituted by the most recent that
encompasses more entities with malignant potential
under the term neuroendocrine neoplasia [2, 5, 6].
Although there are several registries reporting on the
incidence of GEP NENs [7–9] only few registries include
data on NENs of other sites [10–13]. Therefore there is
lack of information on the incidence and the relative fre-
quency of many NEN subgroups including the head and
neck and unknown primary (UP) that remain highly
under-represented in the registries.
The primary endpoint of the study was to describe
NEN subtypes in Greece and to collect information on
the presenting symptoms, diagnostic evaluation, staging
techniques and choice of treatment modalities, in these
patients.
Methods
The neuroendocrine tumor registry in Greece
The Neuroendocrine Tumor Registry was generated by
dedicated specialists involved in the diagnosis and treat-
ment of NEN patients. The team included medical on-
cologists, endocrinologists and gastroenterologists from
eight academic and non-academic tertiary hospitals with
an established experience in the management of NEN
patients. The registry was funded by IPSEN Epe, Greece.
IPSEN had no influence on the setup of the database,
data acquisition or data analysis and had no access to
raw data. The design of the study was descriptive, multi-
center and observational open-ended surveillance regis-
try. Approval of the study was obtained from each
Institutional Review Board & Ethics Committee accord-
ing to the Declaration of Helsinki and Good Clinical
Practice, as well as to the EU regulations [directives 95/
46/EC (24/10/1995),2001/20/EC (04/04/2001) and (EC)
45/2001]. Regulatory approval was obtained from the
National Organization for Medicines (EOF). All patients
signed a written informed consent for participation in
the study. No children were involved in this database.
Data acquisition
A dedicated database software (TMS, Athens, Greece)
was built with contribution by all authors during three
specifically dedicated days. The items to be included
were decided upon by specialists (medical oncologists,
gastroenterologists and endocrinologists) experienced in
the care of patients with NEN. This prospective survey
was conducted in eight Greek referral centers and re-
cruitment of NEN patients was started after October
2010. The feasibility and utility of the database was
tested in a pre-test platform and necessary modifications
were performed. The resulting database consisted of
data fields divided in 18 sections including demograph-
ics, symptoms, tumor characteristics, diagnostic proce-
dures, treatments modalities and outcome. If a patient
received a treatment (e.g. somatostatin analogues) for
more than one continuous treatment period, then the
separate treatment periods and the response to each of
them were documented as separate outcomes. Possible
answers were either split into “yes” or “no” or selected
from a drop-down menu. All physicians were trained
and were responsible for the introduction of the studied
features in the registry. One trained study monitor vis-
ited each center, reviewed the patients’ medical files pro-
vided by the institution and assessed the quality of data
insertion to the database.
All patients were entered in the database, by trained
doctors, with their initials, date of birth and date of
histopathology diagnosis to exclude the possibility of
more than one recordings of the same patient. Once the
duplicates were removed this information was excluded.
In the case of genetic syndrome data acquisition
depended on its positive documentation of items. If for
example multiple endocrine neoplasia (MEN) was docu-
mented either as a report of the genetic analysis or
stated as diagnosis by the physician, the patient was doc-
umented as ‘MEN-positive’. In the database inserted pa-
rameters included also details on the diagnostic
procedures and therapies applied. Patient data were spe-
cifically checked to avoid double insertions from differ-
ent centers and in that case data were merged.
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Patient inclusion
Inclusion criteria were diagnosis of NEN histologically
confirmed after October 2010 and a patient’s signed in-
formed consent. Patients were excluded if they had a
small or large cell lung cancer histology or if they were
not actively followed up. Histological classification ap-
plied was the WHO 2010 classification [2] and sta-
ging was assessed according to the 7th AJCC Staging
system [14].
Statistical analysis
We performed an interim analyses after two years of pa-
tient recruitment in the registry. Continuous variables
were expressed either with the use of the mean and the
standard deviation or with the median and the minimum
and maximum values depending on their distribution.
The normality of the distribution of values was exam-
ined with the use of the Shapiro-Wilk test. Categorical
variables were expressed as percentages (%). Statistical
comparison between groups was performed with the use
of Student’s t test or with the Mann Whitney U test
when the distribution of variables was normal or not, re-
spectively. Distribution of continuous variables between
more than two groups was tested with the use of
ANOVA or Kruskal-Wallis test, depending on the nor-
mality or not of their distribution. Differences in cat-
egorical variables were tested with the use of the Fisher’s
Exact test. All statistical analyses were performed with
the use of the IBM SPSS Statistics (ver. 22.0). All statis-
tical tests were two-sided and significance was a priori
determined at the p = 0.05 level.
Results
Patient population
During the study period, 246 eligible patients were re-
corded in the Greek NET Registry. Of these, 121 (49.2
%) were males. All patients were of Caucasian origin, ex-
cept one of South Asian origin. The median age at diag-
nosis of all patients was 57 years (range 18–82).
Of all patients, 111 (45 %) were referred to the Regis-
try Centers by a physician of a different specialty. Sev-
enty six patients (31 %) were found incidentally during a
diagnostic procedure for an apparently unrelated cause.
One hundred fifty six NENs (63.4 %) were located in the
gastroenteropancreatic system. The clinicopathologic
characteristics are shown in Table 1. The more frequent
localization in the stomach was the corpus, while it was
the head for the pancreas. In the lung the typical NENs
prevailed. The majority of tumors were well differenti-
ated and with Ki-67 ≤ 2.
Of the 228 evaluable patients, 6.5 % had T4 stage (all
GEP NENs), 28 % had lymph nodal infiltration (most
commonly GEP NEN, bronchial and H&N) and 24 %
had metastatic disease most frequently in the UP and
GEP NEN groups. Data regarding the T stage are miss-
ing for 18 UP patients.
Multiple endocrine neoplasia was diagnosed in 14 pa-
tients (6 %), all MEN1. Mean age at diagnosis in patients
with MEN1 syndrome was 48.8 ± 19 years compared to
56 ± 14 years in non-MEN patients (p = 0.131). Eight (57
%) had parathyroid hyperplasia, 3 (21 %) pituitary aden-
oma and 4 (29 %) adrenal adenomas. Neuroendocrine
tumors associated with MEN1 syndrome involved 4
head and neck, 1 bronchial, 4 GEP, 2 pheochromocyto-
mas and 3 unknown primary (UP). Clinical syndrome
due to hormone secretion was present in 7 patients.












Duodenum 8 (5 %)
Jejunum 5 (3 %)
Ileum 10 (6 %)
Appendix 17 (11 %)
Colon 8 (5 %)
Rectum 18 (12 %)
Head and Neckc 44 (17.9)










≤2 % 166 (72.8)
3–20 % 56 (24.5)
>20 % 6 (2.6)
a20 missing cases
b18 missing cases
cincludes 41 MTC and 3 paragangliomas
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Clinical manifestations of NEN
Of all patients 38 patients (15 %) were asymptomatic, 24
% reported symptoms related to endocrine syndrome
and 61 % had symptoms related to the presence of the
tumoral mass. The most common clinical symptoms re-
lated to advance disease were dyspepsia (44 %), abdominal
pain (38.6 %) and asthenia (35.8 %) followed by weight loss
(18.3 %) and anorexia (16.7 %). Symptoms related to hor-
monal secretion were less reported and included mainly
flushing (14.5 %), diarrhea (12 %) or both (1 %).
Regarding the symptoms according to tumor location,
in gastroenteric NENs comprised abdominal pain (41
%), asthenia (41 %), weight loss (35 %), dyspepsia (35 %),
and anorexia (17 %). Pancreatic NENs presented most
commonly with abdominal pain (52 %), diarrhea (28 %),
weight loss (28 %), dyspepsia (26 %), and asthenia (21
%). For head and neck NENs (medullary thyroid carcin-
omas and paragangliomas) the most common presenta-
tion was neck swelling (14 %). For adrenal NENs the
most common manifestations were asthenia (25 %),
weight loss (12.5 %), hyperglycemia (12.5 %), and sweat-
ing (25 %). Vein thrombosis was reported in head and
neck NENs (2.5 %) but not in GEP NENs.
Diagnostic procedures
The diagnostic procedures applied according to NEN
site of origin are shown in Table 2. Most commonly per-
formed test for staging was computed tomography (CT;
82 % of patients), followed by Octreoscan (63.4 %). The
procedures leading to the highest percentage of positive
results (% of positive results with imaging compared to
positive histopathological results) were 2-deoxy-2-(18F)
fluoro-D-glucose (18F-FDG) positron emission tomog-
raphy (PET)-computed tomography (CT) scan and mag-
netic resonance.
Investigation of biochemical markers were carried out for
serum chromogranin A (CgA) and for neuron specific eno-
lase (NSE) in the serum of 60 and 43 % of patients respect-
ively and by urinary 5-HIAA in 38 % of patients. The
positive yield of these tests were 89, 28 and 33 % respect-
ively, most commonly all three positive in NEN of UP. In
patients with a suspected functioning NEN additional
hormonal assessment included insulin (6.5 %), gluca-
gon (4.1 %), gastrin (40.7 %) and VIP (3.3 %).
Histopathological characteristics
The histopathological features of all NEN patients are
shown in Table 1. Specific characteristics such as vascular
invasion, local infiltration and differentiation grade in rela-
tion to primary site are presented in Table 3. Local infiltra-
tion was present in 55 (38.7 %) and vascular invasion in
23 (16.7 %) of the 156 patients with GEP NENs. Ki-67 la-
beling index (LI) was carried out in 228 (93 %) NENs. The
distribution of Ki-67 according to the primary site is
shown in Table 3 and according to gender and staging in
Table 4. Immunohistochemical staining for serum CgA,
synaptophysin and somatostatin receptors (SSTR-2) was
done in 186 (76 %), 162 (66 %) and 43 (17 %) of the entire
cohort and was positive in 165 (89 %), 147 (91 %) and 31
(72 %) of the tested patients respectively.
Therapeutic interventions
Treatments applied in NEN patients are shown in
Tables 4, 5 and 6.
Table 2 Diagnostic procedures used for staging, according to primary site (absolute number performed and % positive yield)
Diagnostic Procedure Head &Necka Bronchial GEP Pheochromocytoma Unknown Primary Total
N = 44 N = 16 N = 156 N = 6 N = 24 N = 246
(18) F-FDG PET/CT 6 (100.0) 1 (100.0) 3 (66.7) 0 (0.0) 1 (0.0) 11 (81.8)
Magnetic Resonance 12 (81.8) 4 (100.0) 52 (69.2) 3 (100.0) 14 (78.6) 85 (75.0)
Endoscopic Ultrasound 1 (0.0) 0 (0.0) 21 (81.0) 0 (0.0) 5 (60.0) 27 (74.1)
Bronchoscopy 0 (0.0) 7 (100.0) 0 (0.0) 0 (0.0) 3 (0.0) 10 (70.0)
MIBG 1 (0.0) 0 (0.0) 1 (100.0) 5 (80.0) 3 (33.3) 10 (60.0)
Enteroclysis 0 (0.0) 0 (0.0) 4 (75.0) 0 (0.0) 1 (0.0) 5 (60.0)
Computed Tomography 33 (78.8) 16 (93.8) 126 (43.2) 4 (100.0) 23 (81.8) 202 (58.5)
Abdominal Ultrasound 5 (0.0) 3 (33.3) 65 (50.8) 4 (100.0) 13 (92.3) 90 (55.6)
Gastroscopy 4 (0.0) 3 (0.0) 105 (60.0) 0 (0.0) 14 (14.3) 126 (51.6)
Octreoscan 16 (68.8) 11 (54.5) 107 (44.9) 2 (50.0) 20 (65.0) 156 (50.6)
Colonoscopy 2 (0.0) 2 (0.0) 71 (38.0) 0 (0.0) 15 (0.0) 90 (30.0)
Bone Scan 22 (18.2) 12 (25.0) 10 (22.2) 4 (25.0) 11 (18.2) 59 (20.7)
Endoscopic Capsule 0 (0.0) 0 (0.0) 10 (30.0) 0 (0.0) 6 (0.0) 16 (18.8)
x-Ray 33 (0.0) 15 (100.0) 85 (2.4) 2 (0.0) 17 (17.6) 152 (13.2)
2-deoxy-2-(18F) fluoro-D-glucose: positron emission tomography/computed tomography (18F-FDG PET/CT), n: number of patients
aincludes 41 MTC and 3 paragangliomas
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Somatostatin analogs were administered in 135 pa-
tients. Lanreotide 60–120 mg and Octreotide 20–30 mg
LAR was delivered for a total number of 1378 and
2473 months, respectively. Improvement of symptoms
was observed in 68.2 %, stabilization in 25.9 % and de-
terioration in 5.8 % of the patients. There was no differ-
ence between the symptom responses observed with the
two analogues (p = 0.295), even after controlling for the
different distribution in Ki-67 LI categories in a multi-
nomial logistic regression.
Chemotherapy was given in 22 patients and targeted
therapies in 15 patients. Interferon was recorded as
treatment in only 2 patients. Bevacizumab, an anti-
VEGF monoclonal antibody, was delivered in 4 GEP
NEN patients. Peptide Receptor Radionuclide Therapy
was delivered in 17 patients and radiotherapy in 9 pa-
tients. Surgical excision was applied in 193 patients
with complete excision achieved in 164 patients, all
with Ki-67 < 20 % (Table 5). Local therapies in pa-
tients with liver metastases were applied on 15 occa-
sions (Table 6).
Table 3 Distribution of vascular invasion, local infiltration, differentiation grading and Ki-67 LI in relation to primary site (absolute
number and % of patients)
Clinicopathologic
features
Head &Necka Bronchial GEP Pheochromocytoma Unknown Primary Total
N = 44 N = 16 N = 156 N = 6 N = 24
Vascular invasion 13 (28.2) 5 (10.8) 23 (50.0) 2 (4.3) 3 (6.5) 46 (100.0)
Local infiltration 22 (24.4) 6 (6.6) 55 (61.1) 2 (2.2) 5 (5.5) 90 (100.0)
Differentiation grading
G1 22 (16.6) 10 (7.5) 84 (63.6) 4 (3.0) 12 (9.0) 132 (100.0)
G2 18 (24.6) 6 (8.2) 42 (57.5) 2 (2.7) 5 (6.8) 73 (100.0)
G3 1 (4.7) 0 (0) 17 (80.9) 0 (0) 3 (14.2) 21 (100.0)
Ki-67 labelling index
Ki-67≤ 2 34 (20.4) 13 (7.8) 104 (62.6) 5 (3.0) 10 (6.0) 166 (100.0)
Ki-67 3-20 3 (5.3) 3 (5.3) 39 (69.6) 1 (1.7) 10 (17.8) 56 (100.0)
Ki-67 > 20 0 (0) 0 (0) 3 (50.0) 0 (0) 3 (50.0) 6 (100.0)
aincludes 41 MTC and 3 paragangliomas
Table 4 Distribution of Ki-67 labelling index according to gender,
stage, type of treatment








Male 82 (74.5) 24 (21.8) 4 (3.6) 110 (100.0)
Female 84 (71.2) 32 (27.1) 2 (1.7) 118 (100.0)
Stage TNM
Τ0 16 (84.2) 3 (15.8) 0 (0) 19 (100.0)
Τ1 68 (82.9) 14 (17.1) 0 (0) 82 (100.0)
Τ2 16 (64.0) 9 (36.0) 0 (0) 25 (100.0)
Τ3 17 (54.8) 11 (35.5) 3 (9.7) 31 (100.0)
Τ4 4 (28.6) 10 (71.4) 0 (0) 14 (100.0)
ΤΧ 45 (78.9) 9 (15.8) 3 (5.3) 57 (100.0)
Ν0 111 (78.2) 30 (21.1) 1 (0.7) 142 (100.0)
Ν1 39 (60.9) 20 (31.3) 5 (7.8) 64 (100.0)
ΝΧ 16 (72.7) 6 (27.3) 0 (0) 22 (100.0)
Μ0 97 (81.5) 22 (18.5) 0 (0) 119 (100.0)
Μ1 29 (52.7) 21 (38.2) 5 (9.1) 55 (100.0)
ΜΧ 40 (74.1) 13 (24.1) 1 (1.8) 54 (100.0)
Type of treatment
Lanreotide 52 (69.3) 20 (26.6) 3 (4.1) 75 (100.0)
Octreotide 85 (71.4) 33 (27.7) 1 (0.9) 119 (100.0)
Sunitinib 5 (50.0) 5 (50.0) 0 (0) 10 (100.0)
Everolimus 3 (60.0) 2 (40.0) 0 (0) 5 (100.0)
Chemotherapy 11 (50) 9 (40.9) 2 (9.1) 22 (100.0)
Table 5 Primary surgery performed in NEN patients (n)





Head and Neck 40 4 44
Lung 8 2 10
GEP 110 20 130
Pheochromocytoma 4 2 6
Unknown Primary 2 1 3
Type of Surgery (n)
Open Surgery 128
Endoscopic/Laparoscopic Excision 65
GEP gastroenteropancreatic, n number of patients
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Deaths observed
During the follow-up period of the registry and at the
time of the analyses 10 deaths were documented, corre-
sponding to 4.1 % of the registry population. The pri-
mary sites of origin of these patients were 6
gastroenteric, 2 pancreatic and 2 pheochromocytomas.
Discussion
This study presents for the first time the data of the
NET registry in Greece focusing on the epidemiologic
and clinico-pathologic characteristics as well as the
therapeutic modalities applied in patients with all type of
NENs except small and large cell lung cancer.
Greece is a European country with a reported popula-
tion of 11 million in 2012 (http://countryeconomy.com/
demography/population/greece). This partly explains the
small number of recorded patients (246) presented in
the participating centers during the first two years of this
observational study. Taken into consideration that the
eight centers participating in the study do not cover for
the entire population definitive conclusions on the inci-
dence of NEN tumors cannot be made.
Only few cancer NEN registries exist in the USA and
Europe, mostly national. According to the SEER data-
base (seer.cancer.gov website), that includes information
on 7,262,696 cancer patients, covering for 28 % of the
USA population the incidence of NENs in 2004 is 5.25/
100.000 inhabitants [15]. On the other hand, data on the
incidence of NENs in Europe, is limited and is usually re-
ported by anatomic location, most commonly GEP NENs
[8, 16]. Specifically, in one study including NENs of all
sites, except lung, conducted by the RareCare Working
Group, the overall incidence rate was 25/1,000,000 in total
but it was highest when patients older than 65 years of
age were considered (40 per 1,000,000) [17].
In our registry, the median age at diagnosis and the
gender’s ratio were in accordance to those reported in
other published registries [4, 10, 12]. We found the
gastroenteropancreatic tract being the most common
followed by the head and neck and UP. This is slightly
different from that reported in one study from the Medi-
terranean area with pancreas and lung being the com-
monest primaries, where it was found that 63 % were
GEP-NENs, 33 % thoracic-NENs including thymic, 4 %
UP-NEN [10]. This difference is probably due to the fact
that there was no center for lung NENs participating in
our registry. With respect to the GI tract we found that
gastric (35 %), pancreatic (23 %) and rectal NENs (12 %)
were the commonest primary sites. An inverse frequency
was found in the Italian study as the pancreatic primary
(31 %) was commonest compared to gastric (10 %) [10].
The presenting symptoms of our patients were related to
endocrine syndrome in 24 %, and to mass effect in 61 %,
most commonly dyspepsia, similarly to our previous retro-
spective study [18]. Although only 15 % of patients were
completely asymptomatic, the diagnosis was considered ‘in-
cidental’ in 30.9 % as many patients had vague and under-
reported symptoms recognized after the diagnosis. In line
with our study a registry from Italy reported that the first
symptoms of the disease were related to tumor burden in
46 %, endocrine syndrome in 23 %, while the diagnosis
was fortuity in 29 % of cases [10].
Six percent of our patients had MEN syndrome diag-
nosed earlier compared to patients with sporadic NENs.
Multiple endocrine neoplasia associated NEN frequency
was not different from that reported in an Italian (7 %), a
Spanish (5 %) and a Japanese registry (4.3 %) [8, 10, 19].
As for other tumors associated with hereditary syndromes,
NENs associated with MEN mandates genetic screening
of the relatives, different surveillance methods and treat-
ments for the involved patients [20, 21].
The differentiation grade and Ki-67 LI are not only ob-
ligatory requirements of the pathological classification
system but represent the upmost important prognostic
factors and may help tailor treatment in NEN patients
[22]. Descriptions regarding the Ki-67 LI and differenti-
ation grade are lacking in the published NEN registries
and this is due not only to the frequent change in the clas-
sification system but also to the underreporting of the Ki-
67 in the histological diagnosis [13]. For 93 % of our histo-
logical specimens Ki-67 LI was counted and found most
commonly <2 %. With respect to the differentiation grade
we could find only one similar study that reported a 52 %
of well differentiated neuroendocrine tumors (NETs) and
a 13 % of poorly differentiated NEC [10].
Head and neck was the second most common (20 %)
primary site in our registry and included medullary tumors
and paragangliomas. To our knowledge there is no infor-
mation from other registries on these NENs and thus we
cannot have comparable data. One possible explanation is
that only in the past few years medullary tumors were in-
cluded in the large family of NENs.
Table 6 Surgery and debulking procedures performed in NEN




(all Ki-67 < 20 %)
Patients with
Liver Metastases
Total number: 49 34 GEP, 11 UP, 3 lung,
1 pheochromocyroma
Liver Metastasectomy 6 4 GEP, 1 Lung, 1
unknown primary
Chemoembolization 3 GEP




Total number: 6 4 GEP, 1 lung, 1
unknown primary
Surgical Excision 1 GEP
GEP gastroenteropancreatic, UP unknown primary
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NENs of UP was the third most frequent subtype (9.8
%) in our registry, most commonly of Ki-67 LI > 2 % and
G2/G3. A European study reported a lower incidence (4
%) and a USA study 13 % of UP [10, 15]. By definition
NEN of UP site refers to a group of patients with locally
advanced disease such as regional lymphadenopathy or
most commonly metastatic disease [23]. It cannot be
identified if these tumors arise from an occult gastro-
intestinal or pulmonary primary site or else from a mul-
tipotent stem cell [24]. One explanation for this high
frequency of UP is the non-availability in our country of
Gallium-68 PET/CT and DOPA PET/CT that have a
higher sensitivity for the identification of NEN primaries
such as GEPs and medullary/paragangliomas respectively
[25, 26]. A recent systematic review of the studies pub-
lished in the literature did not identify differences in the
biology of UP NENs or in the outcome of these patients
compared to NEN patients with known primary
matched for grade [27].
In our study we found metastatic disease at presenta-
tion in 25 % of patients comprising 17.5 % of well, 37.5
% of moderately and 83 % of poorly differentiated neo-
plasms. Similar findings were reported from the SEER
database as distant metastases at diagnosis comprised 21
% well, 30 % moderately and 50 % poorly differentiated
tumors [15].
In our study we did not find a statistically significant
difference in the distribution of histologies, primaries
and staging between males and females. However, in the
SEER database male patients were more likely to have
metastasis at presentation, than female patients, in a sta-
tistically significant way [15]. We were able to detect in
our tumors local and vascular infiltration two well-
established features of malignant behavior with adverse
prognostic significance [5]. As long term data of our co-
hort is not yet matured we cannot comment on the im-
pact of these features on the survival of our patients.
With respect to diagnostic imaging, in our population
imaging with internationally recommended techniques
such as somatostatin receptor PET/CT imaging with
Gallium-68 and endoscopic ultrasound (EUS) is either
unavailable (68Ga) or accessible in very few sites (EUS).
In our study octreoscan was less sensitive compared to
other procedures such as computed tomography. This is
in line with an earlier study by our group showing that
octreoscan compared to conventional imaging such as
ultrasound and CT is less sensitive for the detection of
liver metastases [28].
The most commonly applied therapy in our cohort
was somatostatin analogs (SSA), octreotide 30 mg LAR
and lanreotide 120 mg Autogel, both with an established
role in the symptom and tumor control of patients with
well and moderately differentiated NENs [29–31]. Re-
cently, in the CLARINET trial, lanreotide 120 mg
Autogel was established for its anti tumoral effect in
both pancreatic and gastroenteric locally advanced or
metastatic neuroendocrine tumors with Ki-67 up to 10
%. In this registry, the response was documented as im-
provement, stabilization or deterioration of the symp-
toms, without the use of the RECIST criteria, since this
was out of the scope of the registry. Similarly to the pre-
viously published studies, our findings indicate an equal
role of the different SSAs in the control of NEN
symptoms.
Other therapies applied in our patients with Ki-67 LI <
20 % included systemic chemotherapy, with either strepto-
zocin/5FU or temozolomide, or a targeted agent such as
everolimus and sunitinib, according to previously published
data [32–35]. Patients with poorly differentiated tumors or
Ki-67 > 20 % were treated with systemic chemotherapy
comprising cisplatin/carboplatin and etoposide doublets ac-
cording to established evidence [36].
Limitations of our study include a) the fact that not all
NENs diagnosed in our country between October 2010
and November 2012 were included in the present regis-
try and b) the lack of information on survival, progres-
sive free survival, recurrences and new metastases. As
long term data of our cohort is not yet matured we can-
not comment on the impact of our findings on the evo-
lution of the disease in general and on overall survival.
Conclusions
We present for the first time the results of a Greek NET
registry that includes NEN from a variety of primary
sites. Our results indicate some differences in the occur-
rence of NENs reported from registries of other Euro-
pean countries and the USA. It is thus important to
develop national registries for the precise description of
the incidence and the handling of NENs and the possible
application of the findings in prevention and pharma-
coeconomics. Based on the reported occurrence of
NENs and the variations in incidence observed in the lit-
erature it is important that each country develops a na-
tional registry for the recording of the incidence and
clinico-pathologic characteristics of these rare tumors
and to improve our understanding of the biology and
survival of these tumors.
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